• McKesson posted the transcript of its Q1 fiscal 2027 earnings call attended by CEO Brian Tyler, CFO Kenny Cheung, and analysts.
• Results beat expectations: revenue rose 8% to USD 105.4 billion; adjusted EPS climbed 20% to USD 9.93; full-year adjusted EPS guidance lifted to USD 44.2-45.
• North American Pharmaceutical revenue grew 5% to USD 86.8 billion; segment profit rose 19% to USD 894 million on specialty mix, launch timing; GLP-1 distribution revenue reached USD 15 billion.
• Oncology and multispecialty revenue jumped 33% to USD 14.2 billion; excluding Core Ventures, revenue growth was about 24%; Florida Cancer Specialists tracked at the high end of deal guidance.
• Medical-Surgical Solutions rebranded as Wellverse ahead of a planned separation; Apollo took about 13% minority stake; business expects to operate as Wellverse from January 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. McKesson Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.